GKOS · NYSE · STOCK
Glaukos (GKOS) Stock Analysis
$165.76
52W $73.16 – $191.62
61/100
$9.77B
-51.0
0.69
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Is GKOS Bullish or Bearish?
Bullish.
Innellis AI committee rates Glaukos Corporation (GKOS) Buy with a composite score of 61/100
, based on 6 analysts with 50% agreement.
Last updated October 10, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +13.92 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -6.08 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Risk Analyst sees a compelling case — low leverage (debt-to-equity 0.11) -- balance sheet can absorb a shock. Portfolio Manager remains cautious — sector concentration is already high (hhi 2796.97). This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Revenue growing 41.5% YoY -- genuine top-line momentum — Growth
- MACD histogram positive -- bullish momentum — Technical
- Low leverage (debt-to-equity 0.11) -- balance sheet can absorb a shock — Risk
Bear Case
- Price-to-book of 9.9x prices in significant intangible value — Value
- ROE of only -27.1% -- cheap may mean cheap for a reason — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 10, 2026
Overall Committee Score
61/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 27%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 9.9x prices in significant intangible value
Growth Analyst
bullish
60
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 41.5% YoY -- genuine top-line momentum
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.11) -- balance sheet can absorb a shock
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
60
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2796.97)
Investment Thesis Evolution
Committee score moved marginally from 60.7 to 61.1.
Comparing 2026-10-09 to 2026-10-10 (1 day apart).
Technical Analysis
RSI (14)
53.1
Neutral
MACD Histogram
1.007
Bullish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$99.54
Resistance
$191.30
Bollinger %B
0.66
Inside Bands
Price vs Moving Averages
EMA 9
$163.93
Above
EMA 21
$164.94
Above
EMA 50
$165.16
Above
EMA 200
$142.31
Above
Fundamental Analysis
Valuation
67
Growth
54
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-51.0×
P/B Ratio
14.18×
PEG Ratio
0.45
Dividend Yield
0.00%
52W High
$191.62
52W Low
$73.16
Quality & Growth
ROE
-2860.5%
ROA
-2100.7%
Gross Margin
7912.1%
Operating Margin
-1313.4%
Revenue Growth YoY
—
Debt / Equity
0.15
AI Fundamental Assessment
P/E ratio of -51.0 (inexpensive relative to a 15-40x range); Price-to-book of 14.2x; PEG ratio of 0.5 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -28.6%; Return on assets of -21.0%; Net margin of -30.7%; Gross margin of 79.1%; Current ratio of 5.04 (healthy short-term liquidity); Debt-to-equity of 0.15; Free cash flow per share is negative (-0.21); Most recent quarter beat estimates by 34.9%; 2 consecutive earnings beats; EPS growth decelerating (+35.7% -> +22.2% QoQ); Analyst estimates falling over recent quarters
Get the Full GKOS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →